Published in
Wiley, Journal of Viral Hepatitis, 3(23), p. 227-231, 2015
DOI: 10.1111/jvh.12485
Links
Tools
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin
,
Jean-François Dufour,
T. Asselah,
P. Mantry,
M. Bourlière,
D. Forton ,
M. Maevskaya,
D. Wright,
J. García-Samaniego ,
E. M. Yoshida,
C. Oliveira,
M. Wright,
N. Warner,
A.‐M-M. Quinson
and other authors.
Full text: Download
Abstract
Other ; Faldaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, was evaluated in HCV genotype 1-infected patients who failed peginterferon and ribavirin (PegIFN/RBV) treatment during one of three prior faldaprevir trials. Patients who received placebo plus PegIFN/RBV and had virological failure during a prior trial were enrolled and treated in two cohorts: prior relapsers (n = 43) and prior nonresponders (null responders, partial responders and patients with breakthrough; n = 75). Both cohorts received faldaprevir 240 mg once daily plus PegIFN/RBV for 24 weeks. Prior relapsers with early treatment success (ETS; HCV RNA